Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML.
Publication/Presentation Date
1-4-2021
Abstract
Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax.
Volume
10
Issue
1
First Page
1
Last Page
1
ISSN
2162-3619
Published In/Presented At
Jasra, S., Kazemi, M., Shah, N., Chen, J., Fehn, K., Wang, Y., Mantzaris, I., Kornblum, N., Sica, A., Bachier, L., Goldfinger, M., Gritsman, K., Braunschweig, I., Steidl, U., Shastri, A., & Verma, A. (2021). Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML. Experimental hematology & oncology, 10(1), 1. https://doi.org/10.1186/s40164-020-00186-y
Disciplines
Medicine and Health Sciences
PubMedID
33397455
Department(s)
Department of Medicine
Document Type
Article